Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

• Published in: The New England journal of medicine Vol. 389; no. 18; pp. 1672 - 1684
• Main Authors: Heymach, John V., Harpole, David, Mitsudomi, Tetsuya, Taube, Janis M., Galffy, Gabriella, Hochmair, Maximilian, Winder, Thomas, Zukov, Ruslan, Garbaos, Gabriel, Gao, Shugeng, Kuroda, Hiroaki, Ostoros, Gyula, Tran, Tho V., You, Jian, Lee, Kang-Yun, Antonuzzo, Lorenzo, Papai-Szekely, Zsolt, Akamatsu, Hiroaki, Biswas, Bivas, Spira, Alexander, Crawford, Jeffrey, Le, Ha T., Aperghis, Mike, Doherty, Gary J., Mann, Helen, Fouad, Tamer M., Reck, Martin
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 02.11.2023
• Subjects: Adjuvants, Immunologic - therapeutic use; Administration, Intravenous; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; B7-H1 Antigen - administration & dosage; B7-H1 Antigen - therapeutic use; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - surgery; Chemotherapy; Clinical medicine; Clinical practice guidelines; Combined Modality Therapy; Critical Care; Critical Care General; Death; Hematology; Humans; Immunotherapy; Lung Cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Lymphatic system; Medical screening; Monoclonal antibodies; Neoplasm Recurrence, Local - drug therapy; Non-small cell lung carcinoma; Oncology; PD-L1 protein; Placebos; Pulmonary; Radiation therapy; Small cell lung carcinoma; Statistical analysis; Surgery; Surgery General; Targeted cancer therapy; Treatments in Oncology; Tumors
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2304875

Patients with resectable non–small-cell lung cancer had a greater response and longer event-free survival with preoperative durvalumab plus chemotherapy and adjuvant durvalumab than with chemotherapy alone.